Development of novel optical methods for noninvasive detection of cerebral physiological impairments in a pediatric swine model of traumatic brain injury
Active Grant Awarded
- Award ID
- R01NS146589
- Recipient
-
The Children's Hospital Of Philadelphia UEI G7MQPLSUX1L4
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $673,756
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 4% complete
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded Grant R01NS146589 to The Children's Hospital of Philadelphia Research Institute on September 9, 2026, obligating $673,756 under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders. The award funds development and validation of a novel diffuse optical neuromonitoring device for noninvasive detection of cerebral physiological impairments after pediatric traumatic brain injury, using a pediatric swine model. Aim 1 develops and validates a multimodal non-invasive brain monitoring platform. The device targets cerebral blood flow and oxygenation, cerebral oxygen metabolism, intracranial pressure, and cerebral water content as a marker of edema. The project addresses three barriers to clinical translation: limited signal-to-noise ratio with scalp and skull contamination, lack of edema validation, and lack of data on the prognostic value of diffuse optics. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of May 31, 2031. Place of performance is Philadelphia, PA 19104.
Description
- Abstract
- Pediatric traumatic brain injury (TBI) is the most common cause of morbidity and mortality in children worldwide. After the primary injury, secondary cerebral physiologic derangements (e.g., cerebral ischemia, metabolic distress, intracranial hypertension, and cerebral edema) exacerbate brain damage and worsen outcomes. Early detection of these derangements is critical for developing lifesaving, patient-specific interventions. However, current patient management relies on surrogate brain metrics (e.g., physical exams and vital sign monitoring) and intermittent neuroimaging. Despite its potential value, invasive neuromonitoring is rarely used in pediatric patients. Existing non-invasive alternatives, such as near-infrared spectroscopy (NIRS) and electroencephalography (EEG), provide limited and non-specific information. There is a critical need for non- invasive neuromonitoring technologies to enable early detection of cerebral derangements after pediatric TBI. This proposal seeks to fill this need by developing and validating a novel diffuse optical neuromonitoring device for pediatric TBI. Diffuse optics can non-invasively assess cerebral blood flow and oxygenation (indicators of cerebral hypoxia and ischemia), cerebral oxygen metabolism (reflecting metabolic distress), intracranial pressure, and cerebral water content (as a marker of cerebral edema). However, three critical barriers impede clinical translation: (1) limited signal-to-noise ratio (SNR) and contamination from the scalp and skull tissues, (2) lack of validation for edema detection, and (3) lack of information about the prognostic value of diffuse optics. To address these challenges, aim 1 focuses on the development and validation of a multimodal non-invasive brain monitoring platform combining speckle contrast optical spectroscopy (SCOS) and frequency-domain diffuse optical spectroscopy (FD-DOS) for the first time. In aim 2, anatomically accurate simulations and tissue- mimicking phantoms will be used to develop and refine algorithms that mitigate scalp and skull contamination, enabling direct estimates of cerebral water content. These algorithms will be developed and validated through progressing in silico, in vitro and in vivo studies. Finally, aim 3 will determine the prognostic utility of diffuse optics by combining optical cerebral physiology measurements with blood biomarkers and systemic physiology. This combined approach will be used to predict behavioral outcomes and neuroimaging abnormalities at 14 days after closed head TBI in swine. The inclusion of optical measurements is expected to enhance the accuracy of outcome prediction beyond what can be done with traditional physiological metrics and blood biomarkers alone. Overall, this research addresses a critical GAP in pediatric TBI care by developing a next-generation cerebral monitoring platform capable of real-time, non-invasive assessments of brain physiology. This proposal will provide a comprehensive framework for the development and evaluation of patient-specific, brain-guided interventions and neurotherapeutics to improve outcomes for pediatric TBI.
Quick answers
Who received award R01NS146589?
R01NS146589 was awarded to The Children's Hospital Of Philadelphia by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 9, 2026.
How much is award R01NS146589 worth?
$673,756 has been obligated on R01NS146589.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award